With its share prices in a downward slump, two insiders picked
up nearly 40,000 shares in Supernus Pharmaceuticals (
) this past week. The buying trend started on March 14 when
Gregory Patrick (VP and CFO) and Jack Khattar (President and CEO)
bought 15,000 shares of company stock. More recently, Director
John Siebert added 3,000 shares to his stake on March 21. The
shares traded at $5.50 per share for a total transaction amount
of $16,500. Siebert now holds on to 15,188 shares of Supernus
Siebert added 7,000 shares in Dec. 2012 before the price per
share fell. Since that buy the price per share is down 31.7%.
Siebert has been a member of the Board since 2011. He has been
the Chairman and CEO of Compan Pharmaceuticals, a veterinary
specialty company, since 2009. He currently chairs the Audit
Committee of the Board at both Primus Pharmaceuticals and Aradigm
On March 22, Director Michael Bigham bought 35,000 shares at
$5.41 per share. The transaction cost him $189,350. Bigham now
owns at least 36,500 shares of Supernus.
Bigham has been a member of the Board since 2006. He currently
works as a partner with Abingworth Management, an international
venture capital firm focusing on life sciences.
Supernus Pharmaceuticals is a company that develops and
commercializes products for the treatment of central nervous
system disorders. The company is also developing product
candidates in neurology and psychiatry to address unmet medical
needs and other opportunities in epilepsy, ADHD and depression.
GuruFocus has reported that the company has extremely low
interest coverage. Supernus Pharmaceutical's earnings cannot
currently cover its interest expense. If this continues, the
company might have to issue more debt.
The company released this statement in regards to 2013 financial
In order to support both product launches and the continued
development of our pipeline, we project cash burn for the year to
range from $95 million to $105 million. We believe our cash, cash
equivalents, and marketable securities as of Dec. 31, 2012 should
be sufficient to fund operations into the fourth quarter of
For more information on Supernus Pharmaceuticals, look at their
There are no gurus that hold any stake in Supernus
With its shares down 5.44%, Supernus trades at $5.56.
For more information on insider trading at Supernus look at the
Supernus Insider Trade History page.About GuruFocus:
GuruFocus.com tracks the stocks picks and portfolio holdings of
the world's best investors. This value investing site offers
stock screeners and valuation tools. And publishes daily articles
tracking the latest moves of the world's best investors.
GuruFocus also provides promising stock ideas in 3 monthly
newsletters sent to